CytomX Therapeutics, Inc. CTMX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-10.12
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $76.2M | -$17.4M | — | -$75.8M | $99.0M |
| 2024 | $138.1M | $31.9M | — | -$86.5M | -$456,000 |
| 2023 | $101.2M | -$569,000 | — | -$56.9M | -$47.4M |
| 2022 | $53.2M | -$99.3M | — | -$112.5M | -$85.8M |
| 2021 | $37.3M | -$115.9M | — | -$120.6M | -$459,000 |
| 2020 | $100.4M | -$32.9M | — | $3.0M | -$7.8M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.12 (distress)
- Working capital / assets 0.642
- Retained earnings / assets -4.697
- EBIT / assets -0.148
- Equity / liabilities 1.884
Source: SEC EDGAR filings · CIK 0001501989 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.